湖南景峰医药股份有限公司第八届董事会第四十五次会议决议公告

Group 1 - The company held its 45th meeting of the 8th Board of Directors on February 9, 2026, via communication methods [3][5] - All 9 directors participated in the voting process, with unanimous approval for the resolutions [4][7] - The meeting was chaired by acting chairwoman Zhang Li, and senior management attended [5] Group 2 - The board approved the nomination of Ms. Li Xiaoguang as an independent director candidate, who meets the qualifications set by relevant regulations [6] - Upon approval by the shareholders' meeting, Ms. Li will also serve as the chair of the Compensation and Assessment Committee and a member of the Nomination Committee [6] - The independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange before being submitted for shareholder approval [6] Group 3 - Ms. Li Xiaoguang has a distinguished background, including roles in arbitration and legal advisory, and has received multiple accolades for her contributions [10] - She does not hold any shares in the company and has no relationships with major shareholders or other board members [11] - Ms. Li's qualifications comply with the requirements of the Company Law and relevant regulations [11]